Nexsen Highlights Point-of-Care GBS Strategy at Global ISSAD 2026 Conference

Nexsen Limited (ASX:NXN) (**Nexsen** or the **Company**) is pleased to announce its participation as a sponsor, presenter and exhibitor at the International Symposium on Streptococcus agalactiae Disease (**ISSAD**) 2026, being held in Nairobi, Kenya over 23-26 February 2026. ISSAD is a leading biennial global conference focused on Group B Streptococcus (**GBS**), bringing together clinicians, researchers, public health organisations and industry stakeholders involved in the prevention and management of GBS-related disease.

Invited Presentation

Nexsen's Chief Innovation Officer, Distinguished Professor Vipul Bansal, has been invited to present in the session "Advancements in Diagnostics." The presentation, titled: "StrepSure®: A point-of-care lateral flow device for rapid intrapartum diagnosis of GBS colonisation in expectant mothers," will outline the clinical need for rapid intrapartum testing and the development of Nexsen's StrepSure® technology.

A copy of Dist. Prof. Vipul Bansal's presentation is annexed to this announcement.

Sponsorship, Exhibition and Executive Engagement

Nexsen is a conference sponsor and is hosting an exhibition booth showcasing its StrepSure® device, including units manufactured for ongoing clinical evaluation. The Company will engage with clinicians, researchers, public health agencies and potential commercial and strategic partners during the event.

Managing Director, Mr Mark Muzzin is attending ISSAD 2026 as part of Nexsen's executive leadership presence, supporting high-level discussions with global health institutions, industry participants and prospective partners.

ISSAD 2026 includes participation from major global health organisations and industry sponsors, including the Bill & Melinda Gates Foundation and Pfizer. While many industry participants are focused on vaccine-based prevention strategies, Nexsen's participation highlights its focus on point-of-care diagnostic solutions to support clinical decision-making at the time of delivery.

Clinical Need and Market Context

Timely identification of maternal GBS colonisation during labour remains a recognised clinical challenge. Current approaches often rely on laboratory-based testing or antenatal screening performed weeks prior to delivery, which may not reflect colonisation status at the time of birth.

In the United States and other major markets, there are currently limited regulatory-cleared point-of-care diagnostic options designed to deliver actionable results within approximately 30 minutes in the intrapartum setting.

Testing close to delivery can support appropriate clinical decision-making, including targeted use of intrapartum antibiotic prophylaxis, with the aim of reducing neonatal GBS infection while supporting antimicrobial stewardship.

Above: Managing Director Mark Muzzin and Chief Innovation Officer Vipul Bansal at ISSAD.

Development Status

StrepSure® is currently under clinical evaluation and has not yet received regulatory approval for commercial use in any jurisdiction.

Participation in ISSAD 2026 provides Nexsen with an opportunity to increase international awareness of its technology and to engage with key stakeholders across clinical, public health and commercial sectors.

–ENDS–

ASX release authorised by the Managing Director.

For more information, please contact:

Corporate Enquiries
Nexsen Limited
e: corporate@nexsen.bio
w: nexsen.bio

Suite 1005, 4 Bridge Street
Sydney NSW 2000

Company Secretary
Reign Advisory
e: NXN@reignadvisory.com
p: + 61 2 9174 5388

Scan the QR code to join Nexsen's Investor Centre or visit https://investors.nexsen.bio

About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer (which applies to the enclosed Presentation)

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims','believes','expects','may','will','could','should','seeks','intends','estimates','plans','assumes','envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.

StrepSure®

A point-of-care lateral flow device for rapid intrapartum diagnosis of GBS in expecting mothers

Nexsen

ASX:NXN

ISSAD Global Conference on Group B Strep, Nairobi, Kenya – 23-25 Feb 2026

Distinguished Professor Vipul Bansal, FRSC

Melbourne, Australia

Chief Innovation Officer & Chairman of Advisory Board
vb@nexsen.bio

Nexsen

Founding Director, Sir Ian Potter NanoBioSensing Facility
vipul.bansal@rmit.edu.au

RMIT UNIVERSITY

Rapid lab-grade accuracy in diagnosis, at the point-of-care

Nexsen is developing a suite of point-of-care diagnostics built for speed, scale and accessibility.

Through a proprietary platform technology, the Company is focusing on addressing areas of significant unmet clinical needs, where faster answers can improve clinician workflows and in turn patient outcomes.

- A clinical-stage company with near-term market roll-out
- Problem and use-case-led model
- Co-designed with clinicians, end-users and key stakeholders
- Scalable technology platform

Use-case led diagnostic portfolio

Sir Ian Potter NanoBioSensing Facility at RMIT University (2013–)

Vision

Transforming our health, environment & society through **enabling timely interventions**

Mission & the key enabler

Drive an end-to-end MedTech ecosystem from Discovery to Products to Clinical Uptake via **Partnerships** across Industries, Hospitals, End-users & Regulatory Agencies

Technical capabilities leading to strong IP positioning

Biomarker discovery I Nanomaterials I **Nano-bio interactions** I Bioconjugate chemistry Bio- & chemo-metrics I Machine learning I Device fabrication I **Translation**



The key clinical gap in GBS management

The scale of the problem

- 135 million annual births
- 1 in 5 expecting mothers carry GBS
- GBS transmission from mothers to babies is the leading cause of early onset neonatal sepsis

The current standard-of-care

- An enrichment-culture based vaginal-rectal GBS test in Week 36-37 **(takes 2-3 days)**
- If GBS-positive OR high-risk >>> Administer IAP (intrapartum antibiotic prophylaxis)

Why is the current standard-of-care not ideal?

- GBS colonisation is known to change between antepartum testing & labour
  - ~5-10% False negatives at delivery >>>> Undertreatment risk (No IAP)
  - ~10-20% False positives at delivery >>>> Over-treatment risk (More AMR)

Universal screening
vs
Risk-based management

StrepSure® – A rapid 20-min test at Intrapartum

Aiming to reset the GBS Care by enabling PRECISION IAP

Other efforts in GBS Management

- Maternal Vaccines (a road ahead)
  - Incomplete protection - limited to certain serotypes
  - High regulatory burden – large studies, vaccine safety paramount for regulatory use
  - Expected uptake slow once available
  - Ongoing need for GBS status validation (e.g., pre- and post-vaccine administration)

- FDA-approved PCR-based intrapartum tests
  - Require a CLIA-certified lab (e.g. pathology)
  - Lacks true bedside POC capability

StrepSure® aims to provide a true point-of-care bedside test to bring rapid GBS diagnosis in delivery rooms, enabling Precision IAP, and filling a key gap in intrapartum care

Even once vaccines become available, intrapartum testing will still be needed to guide Precision IAP

StrepSure® is the next-generation user-friendly RAT

A sophisticated lateral-flow technology incorporating:

- Ultrabright nanoparticles
- High affinity bioreceptors, such as aptamers with outstanding specificity
- Novel bioconjugation and flow chemistry with optimized device engineering parameters

Not-so-sophisticated for users: simple to use

- Ideal for GBS screening in LMIC and remote settings
- No need for enrichment culture prior to testing
- Does not need electricity, laboratory infrastructure or technical skill sets



Bansal et al., Trends in Analytical Chemistry, 2024, 172, 117573.

StrepSure® where are we?

Analytical performance validation completed

- StrepSure® can detect all GBS serotypes at clinically-relevant concentrations with 100% specificity, showing its potential to support global GBS surveillance and diagnostic efforts as serotypes vary across the globe

Non-interventional clinical validation in-progress

- Current trial site – Northern Hospital, Melbourne, AU – ongoing recruitment and performance validation
- Significant global interest from OBGYN Clinicians to perform local clinical validation
- Additional clinical sites across AU, Asia and the USA identified, engaged with, and ready to be on-boarded to align with our multi-jurisdiction regulatory approval and product launch strategy
- Trial design stipulates minimal change in clinical work-flow. The NH trial team found "Device simple to use and well-suited to the workflow of busy labour wards"

Regulatory positioning and anticipated clinical availability of StrepSure® for maternal GBS diagnostics

	Q1 CY2026	Q2 CY2026	Q3 CY2026	Q4 CY2026
Engagement with US-FDA – an upcoming pre-sub meeting to feed into our trial/ regulatory strategy				
Quality Management System (QMS) incl. ISO 13485 certification received , a pre-requisite for regulatory submissions in several jurisdiction beyond the US				
Post-completion of clinical studies, an FDA 510(k) application anticipated to be submitted in Q4, CY2026				

StrepSure® is anticipated to be available for clinical use at least in one jurisdiction in CY2026

Contact Information

Nexsen

Nexsen Limited (ASX:NXN)

Corporate
corporate@nexsen.bio
www.nexsen.bio

Registered Address
Suite 1005, 4 Bridge Street,
Sydney NSW 2000

Investors
investors@nexsen.bio
www.investors.nexsen.bio

Distinguished Professor Vipul Bansal, FRSC

Chief Innovation Officer & Chairman of Advisory Board
vb@nexsen.bio
Nexsen

Founding Director, Sir Ian Potter NanoBioSensing Facility
vipul.bansal@rmit.edu.au
RMIT UNIVERSITY